Literature DB >> 30372807

Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.

Marzieh Ghanbarian1, Ali Afgar2, Reza Yadegarazari3, Rezvan Najafi4, Ladan Teimoori-Toolabi5.   

Abstract

Oxaliplatin as a component of (Neo-) adjuvant chemotherapeutic regimens is administered to colorectal cancer patients. Unfortunately, the acquisition of resistance to this drug in nearly 90% of metastatic patients rendered it as an ineffective drug. Therefore, resistance mechanisms to this drug should be elucidated. There are different genes like GSTP1 and ABCB1 which are responsible for oxaliplatin resistance. We hypothesized that miR-129-5p, miR-302c-5p, miR-3664-5p, mir-3714 and miR-513a-3p are targeting ABCB1 gene, while GSTP1 was predicted to be the potential target of miR-3664-5p, mir-3714 and miR-513a-3p. In order to study this hypothesis, resistant colorectal cell lines were generated through intermittent exposure of HCT116, SW480 and HT29 to the increasing doses of oxaliplatin. MTT assays validated this resistance induction. Expression of ABCB1 and GSTP1 in addition to their targeting miRNAs in different cell lines were studied by quantitative real time PCR in the cell lines. Even though in comparison with HCT116 and SW480 cell lines, GSTP1 expression was reduced in resistant cells, ABCB1 expression was upregulated in these cell lines. On the other hand, HT-29 resistant cells showed elevated GSTP1 and unchanged ABCB1 levels. While miR-302c-5p level was downregulated in resistant cell lines, miR-129-5p and miR-3664-5p level showed different pattern of reduction in the resistant SW480 and HCT116 cell lines. GSTP1 level was correlated directly with miR-513a-3p and miR-3664-5p in all SW480 and HCT116 derived cell lines, however in HT-29-OXR1, GSTP1 level was correlated inversely with miR-3664-5p. In conclusion, upregulation of ABCB1 can be considered as the crucial component of poor response to oxaliplatin which is likely controlled by miR-302c-5p.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ABCB1; Colorectal neoplasiaa; Drug resistance; GSTP1; Oxaliplatin; miRNA

Mesh:

Substances:

Year:  2018        PMID: 30372807     DOI: 10.1016/j.biopha.2018.09.112

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Inhibition of semaphorin 4D enhances chemosensitivity by increasing 5-fluorouracile-induced apoptosis in colorectal cancer cells.

Authors:  Golnaz Rashidi; Mahsa Rezaeepoor; Chiman Mohammadi; Ghasem Solgi; Rezvan Najafi
Journal:  Mol Biol Rep       Date:  2020-09-04       Impact factor: 2.316

Review 2.  MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.

Authors:  Fahima Danesh Pouya; Maria Gazouli; Yousef Rasmi; Dimitra Ioanna Lampropoulou; Mohadeseh Nemati
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

Review 3.  miRNA Clusters with Down-Regulated Expression in Human Colorectal Cancer and Their Regulation.

Authors:  Paulína Pidíkova; Richard Reis; Iveta Herichova
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

Review 4.  Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.

Authors:  Lei Zhang; Xiulan Zheng; Wen Cheng; Xuefei Zhang; Lingling Wang; Haixia Li
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

5.  Exosome-Reversed Chemoresistance to Cisplatin in Non-Small Lung Cancer Through Transferring miR-613.

Authors:  Delong Li; Debin Meng; Rungui Niu
Journal:  Cancer Manag Res       Date:  2020-09-03       Impact factor: 3.989

6.  miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling.

Authors:  Hu Han; Yan Li; Wan Qin; Lu Wang; Han Yin; Beibei Su; Xianglin Yuan
Journal:  Cancer Cell Int       Date:  2022-01-28       Impact factor: 5.722

7.  Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines.

Authors:  Kei Takuma; Shintaro Fujihara; Koji Fujita; Hisakazu Iwama; Mai Nakahara; Kyoko Oura; Tomoko Tadokoro; Shima Mimura; Joji Tani; Tingting Shi; Asahiro Morishita; Hideki Kobara; Takashi Himoto; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

8.  Screening of molecular targets and construction of a ceRNA network for oxaliplatin resistance in colorectal cancer.

Authors:  Wu Wei; Yang Xi; Xu Jiamin; Zhuang Jing; Han Shuwen
Journal:  RSC Adv       Date:  2019-10-02       Impact factor: 4.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.